Fibao

La misión de esta convocatoria es apoyar la investigación básica, pre-clínica y clínica a través de un programa de becas competitivas, que haga avanzar el conocimiento médico de la proteína PCSK9 en la salud humana, así como promover el desarrollo de la investigación académica emergente y de científicos prometedores de todo el mundo.

Los temas de los proyectos a financiar en esta convocatoria serán los siguientes:

• Pathophysiology of non-diabetic or diabetic dyslipidemia and its relation to atherosclerotic vascular disease, including genetic, transcriptomic, metabolomic, lipidomic, proteomic, and clinical aspects.
• Lipoprotein particles, cellular lipoprotein receptors, and lipid homeostasis.
• Role of PCSK9 in: Lipoprotein (a) metabolism, Tumorigenesis, Immune system, Infectious diseases and Vascular biology.
• Pathophysiology of cardiovascular diseases other than atherosclerosis (e.g., vein graft failure, thrombosis, valvular heart disease, stroke)
• Non-lipid/lipoprotein effects of PCSK9 (e.g., role of PCSK9 in the central nervous system, intestine, pancreas, adrenals, adipose tissue, kidneys, gonads, etc).
• Biochemistry of PCSK9 (structural biology and mechanistic implications).
• Identification of the unmet needs and/or residual risk in high risk. secondary/primary prevention patients that may be addressed by PCSK9 inhibitors (i.e., retrospective database analyses, cohort studies utilizing existing populations, etc.). Such patients will be receiving lipid-lowering therapy in accordance with optimal current standards of care.